登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002019 证券简称：亿帆医药 公告编号：2025-061 二、对公司的影响 公司拟中选产品盐酸去氧肾上腺素注射液、美索巴莫注射液分别于2023年3月、2024年8月收到国家药品 监督管理局核准签发的《药品注册证书》。 本次集中采购是国家组织的第十一批药品集中带量采购，采购周期中，医疗机构将优先使用本次药品集 中采购中选产品，并确保完成约定的采购量。截至本报告披露日，本次拟中选产品销售收入占公司营业 收入比重较小，预计短期内不会对公司业绩产生较大影响。若公司后续签订采购合同并实施，将有利于 上述产品提高药品可及性及公司品牌影响力。 三、风险提示 亿帆医药股份有限公司 关于全资子公司参与全国药品集中采购拟中选的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 2025年10月27日，亿帆医药股份有限公司（以下简称"公司"）全资子公司合肥亿帆生物制药有限公司参 加了国家组织药品联合采购办公室（以下简称"联合采购办公室"）组织的第十一批全国药品集中采购的 投标工作。公司部分产品拟中选本次集中采购。现将 ...

截至发稿，亿帆医药市值为160亿元。 每经头条（nbdtoutiao）——A股突破4000点！十年沉寂终迎爆发，科技主线重塑市场，"慢牛"新格局开 启！ 每经AI快讯，亿帆医药（SZ 002019，收盘价：13.18元）10月29日晚间发布公告称，2025年10月27日， 亿帆医药股份有限公司全资子公司合肥亿帆生物制药有限公司参加了国家组织药品联合采购办公室组织 的第十一批全国药品集中采购的投标工作。公司部分产品拟中选本次集中采购，包括盐酸去氧肾上腺素 注射液等产品。 2025年1至6月份，亿帆医药的营业收入构成为：医药占比85.53%，医药原料及中间体占比11.47%，高 分子材料占比3.0%。 （记者 曾健辉） ...

人民财讯10月29日电，亿帆医药（002019）10月29日公告，公司全资子公司合肥亿帆生物制药有限公司 参加了国家组织药品联合采购办公室组织的第十一批全国药品集中采购的投标工作。公司部分产品(盐 酸去氧肾上腺素注射液、美索巴莫注射液)拟中选本次集中采购。 ...

最新一批国家组织药品集中带量采购27日在上海开标，55种药品全部采购成功，272家企业的453个产品 获得拟中选资格。至此，国家组织集采已覆盖490种药品，药品清单持续扩容。随着国家"团购"药品再 发力，成都企业也积极参与，10月28日晚间，科伦药业和苑东生物两家成都上市医药企业公布了合计14 个产品的拟中标情况。 公司同时表示，近三年研发投入平均占营业收入的比例超过20%，高研发投入带来了较高的转化效率， 2023年至今国内每年均有不少于10个新制剂产品获批上市。 成都日报锦观新闻 记者 刘泰山 编辑: 段琪琳 责编: 高婷 公告同时披露了拟中标产品2023年及2024年的销售收入情况。数据显示，12个拟中标产品中，除复方醋 酸钠林格注射液（250ml、500ml规格）、艾曲泊帕乙醇胺片、奥拉帕利片等少数产品在2023年或2024 年有少量销售收入外，其余多数产品此前销售收入为零。 作为国内大型制药企业，科伦药业近年来持续通过参与国家集采扩大产品市场准入。此次拟中标第十一 批集采的12个产品，进一步丰富了公司在专科用药、抗肿瘤、精神疾病等领域的集采产品管线，有望为 公司长期业绩增长提供支撑。 苑东生物也公告 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本次集中采购是国家组织的第十一批药品集中带量采购，采购周期中，医疗机构将优先使用本次药品集 中采购中选药品，并确保完成约定采购量。公司预计本次中选产品将在2026年第一季度开始执行，对公 司2025年度的经营业绩不会产生影响。本次中选价格与原销售价格相比有一定程度下降，若公司后续签 订采购合同并实施后，将有利于上述产品提高药品可及性。 成都苑东生物制药股份有限公司 关于自愿披露公司参与全国药品集中采购拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于2025年10月27日参加了国家组织药品联合采购办 公室（以下简称"联采办"）组织的第十一批全国药品集中采购的投标工作，公司盐酸去氧肾上腺素注射 液、贝前列素钠片2个产品拟中选本次集中采购。现将相关情况公告如下： 一、拟中选产品基本情况 ■ 注：1、上述拟中标价格以联采办发布的最终数据为准；2、按照相关规定，采购周期内采购协议可以每 年一签，也可以签约至采购周期结束并 ...

人民财讯10月28日电，苑东生物(688513)10月28日公告，公司于2025年10月27日参加了国家组织药品联 合采购办公室组织的第十一批全国药品集中采购的投标工作，公司盐酸去氧肾上腺素注射液、贝前列素 钠片2个产品拟中选本次集中采购。 转自：证券时报 ...

格隆汇10月28日丨苑东生物(688513.SH)公布，公司于2025年10月27日参加了国家组织药品联合采购办 公室（简称"联采办"）组织的第十一批全国药品集中采购的投标工作，公司盐酸去氧肾上腺素注射液、 贝前列素钠片2个产品拟中选本次集中采购。 ...

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

Core Viewpoint - Hainan Pharmaceutical's subsidiary Anhui Hengxing Pharmaceutical has received approval from the National Medical Products Administration for the "Dexamethasone Hydrochloride Injection" registration certificate, which is expected to positively impact the company's development and product line [1] Group 1 - The approved drug is used to treat clinical hypotension caused by vasodilation during anesthesia [1] - The drug is classified as a Category B product under the national medical insurance scheme [1] - The projected domestic hospital sales for Dexamethasone Hydrochloride Injection in 2024 is 119 million yuan [1] Group 2 - The approval will enrich the company's product line and optimize its product structure [1] - The development is seen as a positive influence on the company's growth trajectory [1]